View in EDS

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Saved in:
Bibliographic Details
Title: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Authors: Hortobagyi, G N1 ghortoba@mdanderson.org, Stemmer, S M2, Burris, H A3, Yap, Y S4, Sonke, G S5, Paluch-Shimon, S6, Campone, M7, Petrakova, K8, Blackwell, K L9, Winer, E P10
Source: Annals of Oncology. Jul2018, Vol. 29 Issue 7, p1541-1547. 7p. 1 Diagram, 2 Charts, 2 Graphs.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy155